Lupus kliinilised uuringud osariigis Illinois
14 uuringut haiguse Lupus jaoks otsivad osalejaid osariigis Illinois.
Linnad osariigis Illinois
Ametlik uuringutekst (inglise keeles)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
VärbamineFaas 3
Vanused 16 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06617325Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Willow Rheumatology Wellness, Willowbrook
VärbamineFaas 3
Vanused 12–100 · Kõik sood · Uuendatud 1. okt 2026 · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
VärbamineFaas 3
Vanused 5–17 · Kõik sood · Uuendatud 30. sept 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 25. sept 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
VärbamineFaas 3
Vanused 18–75 · Kõik sood · Uuendatud 25. sept 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
VärbamineFaas 1
Vanused 18–75 · Kõik sood · Uuendatud 25. sept 2026 · NCT07607964A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
VärbamineFaas 2
Vanused 16–70 · Kõik sood · Uuendatud 17. sept 2026 · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
VärbamineFaas 1/2
Vanused 18–70 · Kõik sood · Uuendatud 10. sept 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
VärbamineFaas 1
Vanused 18–74 · Kõik sood · Uuendatud 10. sept 2026 · NCT07085104A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
VärbamineVaatlusuuring
Vanused 16 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
VärbamineFaas 1
Vanused 18–70 · Kõik sood · Uuendatud 28. aug 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
VärbamineFaas 1/2
Vanused 18–65 · Kõik sood · Uuendatud 26. aug 2026 · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
VärbamineFaas 1
Vanused 18–75 · Kõik sood · Uuendatud 10. aug 2026 · NCT06977724Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
VärbamineVaatlusuuring
Vanused 18–110 · Kõik sood · Uuendatud 15. apr 2026 · NCT05934149Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.